Study will allow The Lundquist Institute to determine the multi-generational risks of developing asthma from vaping while pregnant
Investigator(s):
Virender Rehan, MD
LOS ANGELES - Studies have shown that pregnant women who smoke increase the risk of their children having asthma, and that those children—even if non-smokers—can pass it on to their own children, but few objective studies have evaluated the effects of vaporized nicotine and vapor flavorings. Investigators from The Lundquist Institute, under the leadership of Virender Rehan, MD, have received a $2.3 million grant from the National Institutes of Health (NIH) to research this multi-generational effect of vaping, or smoking an electronic cigarette, while pregnant.
New Long-Term Follow-Up Study Published Today in JAMA (Journal of the American Medical Association) Shows Noteworthy Results
Investigator(s):
Rowan T Chlebowski, MD, PhD
LOS ANGELES - The Lundquist Institute announced today a new study published in JAMA (Journal of the American Medical Association) which examined the link between hormonal therapy, particularly estrogen and progestin, and the incidence of breast cancer mortality. The team found that the use of estrogen alone among women who had a prior hysterectomy resulted in a lower rate of breast cancer incidence and mortality.
Psilocybin clinical project will investigate efficacy and safety of a psychedelic compound for those under severe psychological distress from terminal illness
Investigator(s):
Charles Grob, MD
LOS ANGELES – An anonymous donor has committed $1.75 million to The Lundquist Institute for Biomedical Innovation in Torrance, CA to fund a multi-site clinical trial to evaluate the efficacy and safety of the compound psilocybin in individuals with severe psychological distress associated with a terminal medical illness. The donation will also support education and outreach programs related to the use of psilocybin within the field of palliative care.
The Lundquist Institute Awarded a $3M NIH Grant to Explore Better, Safer Treatment for Heart Disease
Study led by Dr. Matthew Budoff will use 20 years of data from Multi-Ethnic Study of Atherosclerosis to determine the impact of extra-coronary calcification
Investigator(s):
Matthew Budoff, MD
LOS ANGELES – A team of investigators from The Lundquist Institute, led by renowned cardiac researcher Matthew Budoff, MD, has been awarded a $3 million R-01 grant award from the National Institutes of Health (NIH) to explore a better way to treat those with heart disease. This will be accomplished by determining whether calcification outside the heart has an impact on the likelihood of developing heart disease and stroke. These findings could have a significant, direct and positive impact on current medical practices, delivering appropriate preventative treatment early on and emphasizing
Many things were halted because of the pandemic, but a partnership to create an inclusive pathway to treat underserved children was not among them
Investigator(s):
Lynda Polgreen, MD, MS, Agnes Chen, MD
LOS ANGELES — Investigators at The Lundquist Institute have teamed up with the Cure Sanfilippo Foundation for a unique clinical trial that explores whether repurposing an existing anti-inflammatory drug can provide relief to children suffering from Sanfilippo syndrome. Often referred to as “childhood Alzheimer’s,” Sanfilippo is a metabolic disorder that leads to rapid neurological deterioration, suffering, and ultimately death.
Renowned reproductive biology expert Wei Yan, MD, PhD, leads class of recruits
Investigator(s):
Wei Yan, MD, PhD, Eiji Yoshihara, PhD, Hua Wang, PhD, Denise Al Alam, PhD, Nicholas Jendzjowsky, PhD
LOS ANGELES — The Lundquist Institute has added six new investigators to its distinguished research faculty, headlined by Wei Yan, MD, PhD, an internationally renowned investigator in reproductive biology. This new class of recruits will arrive on campus between June and September of 2020, with dedicated research space throughout the 11.5-acre campus.
Los Angeles-area biomedical research institute participates in 2000-person trial for potential coronavirus treatment
Investigator(s):
Eric Daar, MD
LOS ANGELES (May 6, 2020) — Today, researchers at The Lundquist Institute began a randomized, double-blind, placebo-controlled clinical trial designed to find out whether hydroxychloroquine and azithromycin reduce hospitalization and/or death in individuals suffering from COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2. This trial, sponsored by the National Institutes for Health, will include 2,000 adults with symptomatic SARS-CoV-2 infections. Under the direction of Dr.
New institute brings together renowned experts focused on biggest health concerns facing women and children
Investigator(s):
Ruey-Kang Chang, MD
LOS ANGELES – Today, The Lundquist Institute, formerly known as the Los Angeles Biomedical Research Institute (LA BioMed), located at Harbor-UCLA Medical Center, held the inaugural meeting of its Institute for Women’s and Children’s Health (IWCH).
Physical inactivity is best predictor of decline in COPD patients, US’ 4th-leading cause of death
Investigator(s):
Harry Rossiter, PhD
LOS ANGELES — Dr. Harry Rossiter, an investigator at The Lundquist Institute (formerly known as LA BioMed) was among the recipients of a $1.55 million grant award from the National Institutes of Health (NIH) to study muscle dysfunction in patients with chronic obstructive pulmonary disease (COPD), the fourth-leading cause of death in the United States.
Tepezza™ is first and only FDA-approved treatment for Thyroid Eye Disease. Approval marks fourth FDA-approved product containing technologies created at The Lundquist Institute.
Investigator(s):
The Lundquist Institute
LOS ANGELES — The U.S. Food and Drug Administration (FDA) approved Tepezza™ for the treatment of Thyroid Eye Disease (TED) on January 21, marking the fourth FDA-approved product containing technologies pioneered at The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), in the last 17 years—and the third in the last five years.